Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-25-248
Official listed status: posted
Closing information: 2027-10-08 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: City or township governments; County governments; For profit organizations other than small businesses; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Native American tribal organizations (other than Federally recognized tribal governments); State governments; Others (see text field entitled "Additional Information on Eligibility" for clarification); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; Special district governments; Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities
Federal synopsis
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.